Elizabeth H.z. Thompson - 24 Mar 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Head of Research & Dev
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
24 Mar 2025
Net transactions value
$0
Form type
4
Filing time
26 Mar 2025, 19:52:56 UTC
Previous filing
03 Jan 2025
Next filing
02 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +91,395 $0.000000 91,395 24 Mar 2025 Common Stock 91,395 $17.23 Direct F1
transaction ACAD Restricted Stock Units Award $0 +26,861 $0.000000 26,861 24 Mar 2025 Common Stock 26,861 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning March 24, 2026.